Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution

Annals of Hematology
S MüllerT Moritz

Abstract

Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently, several cases of gemcitabine-induced HUS have been observed with the overall incidence of gemcitabine-induced HUS estimated at 0.015-0.25%. We here report on four patients who developed HUS following gemcitabine therapy at our institution within the last year (incidence 1.4%). All these patients had advanced-stage disease, were heavily pretreated, and received prolonged gemcitabine application, suggesting that in this subgroup of patients HUS may be more frequently encountered than documented so far.

References

Jun 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J B LesesneP S Schein
Jul 1, 1995·Kidney International·G Remuzzi, P Ruggenenti
Oct 23, 1995·Archives of Internal Medicine·A M MelnykC M Kjellstrand
Dec 1, 1995·Pediatric Clinics of North America·R L Siegler
Jan 1, 1996·Cancer Treatment Reviews·H J GuchelaarA van Knapen
Jan 15, 1997·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Y F Hui, J Reitz
Dec 31, 1997·Journal of the National Cancer Institute·T BrodowiczC C Zielinski
Jul 11, 1998·Anti-cancer Drugs·M E SchiebeM Bamberg
Aug 26, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J PalmisanoA A Kaplan
Aug 8, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Hans von Baeyer
Feb 18, 2003·British Journal of Haematology·Sarah L AllfordUNKNOWN Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology

❮ Previous
Next ❯

Citations

Dec 8, 2004·Der Internist·M Krych
Nov 6, 2008·Expert Opinion on Drug Safety·Constantin A Dasanu
Dec 1, 2009·Critical Care Clinics·Dominique D Benoit, Eric A Hoste
Jan 19, 2016·Kidney Research and Clinical Practice·Hyunjin RyuHajeong Lee
Jan 16, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stuart M LichtmanMatti Aapro
Nov 4, 2006·Néphrologie & thérapeutique·Svetlana KarieGilbert Deray
Mar 18, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jacob G ThomasSuzanne M Norby
Oct 10, 2009·Journal of Clinical Apheresis·Ethan McCaleb GoreMarisa B Marques
Nov 19, 2013·Internal Medicine Journal·J RichmondE Abro
Jun 23, 2010·Journal of Clinical Apheresis·Zbigniew M SzczepiorkowskiUNKNOWN Apheresis Applications Committee of the American Society for Apheresis
Oct 5, 2013·Journal of Chemotherapy·Frederico LealJosé Barreto C Carvalheira
Jul 7, 2007·The Lancet Oncology·Melanie ZupancicFarheen Shah-Khan
Feb 9, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Gwenalyn Garcia, Jean Paul Atallah
Apr 5, 2014·Breast Cancer : Basic and Clinical Research·Victor C KokChien-Kuang Lee
Nov 6, 2018·British Journal of Clinical Pharmacology·Florence DavietNoémie Jourde-Chiche
Jan 14, 2018·BMC Nephrology·Vinod KrishnappaRupesh Raina
Oct 12, 2007·International Journal of Clinical Oncology·Nishant KalraSayed Osama
May 15, 2007·Acta Oncologica·Margret ArnadottirJon Hrafnkelsson
Feb 1, 2014·Clinical Kidney Journal·Norbert Lameire

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.